Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Community Advisory Board (CAB) members:
- People aged 18 or older
- People who speak English
- People who are able to understand the study and are willing to give spoken agreement to take part
- People who are patients at Dana-Farber Cancer Institute (DFCI) and have been in remission from a blood cancer for more than 1 year are preferred (though community members may also be considered)
- People who are pregnant may be eligible, as this study involves no treatments or interventions and poses minimal risk (confirm with trial site)
Investigator participants:
- People aged 18 or older
- People who speak English
- People who are a site investigator or principal investigator on a clinical trial
- People who are not members of the research team running this study
Who may not be able to join:
Community Advisory Board (CAB) members:
- Adults who are not able to give their own consent
- Anyone under 18 years of age, including infants, children, and teenagers
- People who are currently incarcerated
- People who are unwilling or unable to agree to keep trial review materials and discussions confidential, as described in the study guidelines
Investigator participants:
- Anyone under 18 years of age
- People who do not speak English
- People who are members of the research team conducting this study
Note: English is required for all participants because the trial documents being reviewed are written in English and cannot be translated within the timeframes needed for the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew Hantel, MD, Dana-Farber Cancer Institute
Phone: 617-582-9394
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Protocol Review Completion Rate; Protocol Review Completion Rate Within 35 Days; Proportion of Acceptability of Intervention Measure (AIM) Scores of 10 or Greater
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.